Market Overview:
The global hemoglobinopathies market reached a value of US$ 8.36 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 14.8 Billion by 2027 exhibiting a CAGR of 9.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hemoglobinopathies is genetic blood disorder that causes structural and production abnormalities in hemoglobin molecules. Sickle cell, thalassemia, hemoglobin C, and beta-thalassemia are some of the common types of hemoglobinopathies. Hemoglobinopathies are detected by genetic testing, hemoglobin by high-performance liquid chromatography, routine red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), and hemoglobin electrophoresis (Hb ELP) test. Pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet are a few of the most common symptoms hemoglobinopathies. Some of the widely used hemoglobinopathies treatment solutions include antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Hemoglobinopathies Market Trends:
The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, treatment, test type and end user.
Breakup by Type:
- Thalassemia
- Alpha Thalassemia
- Beta Thalassemia
- Sickle Cell Disease
- Others
Breakup by Treatment:
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Blood Transfusion
- Stem-cell Transplantation
- Analgesics
- Antibiotics
- ACE Inhibitors
- Hydroxyurea
- Others
Breakup by Test Type:
- Red Blood Cell (RBC) Count
- Genetic Testing
- High Performance Liquid Chromatography (HPLC)
- Hemoglobin Isoelectric Focusing (Hb IEF)
- Hemoglobin Electrophoresis (Hb ELP)
- Hemoglobin Solubility Test
Breakup by End User:
- Hospitals and Clinics
- Diagnostics Laboratories
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Type, Treatment, Test Type, End User, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation. |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global hemoglobinopathies market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global hemoglobinopathies market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the treatment?
- What is the breakup of the market based on the test type?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global hemoglobinopathies market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hemoglobinopathies Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Thalassemia
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Alpha Thalassemia
6.1.2.2 Beta Thalassemia
6.1.3 Market Forecast
6.2 Sickle Cell Disease
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Treatment
7.1 Blood Transfusion
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Stem-cell Transplantation
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Analgesics
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Antibiotics
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 ACE Inhibitors
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Hydroxyurea
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Test Type
8.1 Red Blood Cell (RBC) Count
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Genetic Testing
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 High Performance Liquid Chromatography (HPLC)
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Hemoglobin Isoelectric Focusing (Hb IEF)
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Hemoglobin Electrophoresis (Hb ELP)
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Hemoglobin Solubility Test
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals and Clinics
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Diagnostics Laboratories
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Bio-Rad Laboratories Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 bluebird bio Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Bristol-Myers Squibb Company
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Danaher Corporation
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Emmaus Life Sciences Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.6 Gamida-Cell Ltd.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.7 Global Blood Therapeutics Inc.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.8 Novartis AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 PerkinElmer Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Pfizer Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Prolong Pharmaceuticals LLC
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.12 Sangamo Therapeutics Inc.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
15.3.13 Sysmex Corporation
15.3.13.1 Company Overview
15.3.13.2 Product Portfolio
15.3.13.3 Financials
15.3.13.4 SWOT Analysis
List of Figures
Figure 1: Global: Hemoglobinopathies Market: Major Drivers and Challenges
Figure 2: Global: Hemoglobinopathies Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Hemoglobinopathies Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Hemoglobinopathies Market: Breakup by Type (in %), 2021
Figure 5: Global: Hemoglobinopathies Market: Breakup by Treatment (in %), 2021
Figure 6: Global: Hemoglobinopathies Market: Breakup by Test Type (in %), 2021
Figure 7: Global: Hemoglobinopathies Market: Breakup by End User (in %), 2021
Figure 8: Global: Hemoglobinopathies Market: Breakup by Region (in %), 2021
Figure 9: Global: Hemoglobinopathies (Thalassemia) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Hemoglobinopathies (Thalassemia) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Hemoglobinopathies (Sickle Cell Disease) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Hemoglobinopathies (Sickle Cell Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Hemoglobinopathies (Other Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Hemoglobinopathies (Other Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Hemoglobinopathies (Blood Transfusion) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Hemoglobinopathies (Blood Transfusion) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Hemoglobinopathies (Stem-cell Transplantation) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Hemoglobinopathies (Stem-cell Transplantation) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Hemoglobinopathies (Analgesics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Hemoglobinopathies (Analgesics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Hemoglobinopathies (Antibiotics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Hemoglobinopathies (Antibiotics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Hemoglobinopathies (ACE Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Hemoglobinopathies (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Hemoglobinopathies (Hydroxyurea) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Hemoglobinopathies (Hydroxyurea) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Hemoglobinopathies (Other Treatments) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Hemoglobinopathies (Other Treatments) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Hemoglobinopathies (Genetic Testing) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Hemoglobinopathies (Genetic Testing) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Global: Hemoglobinopathies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Global: Hemoglobinopathies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Global: Hemoglobinopathies (Diagnostics Laboratories) Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Global: Hemoglobinopathies (Diagnostics Laboratories) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Global: Hemoglobinopathies (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Global: Hemoglobinopathies (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: North America: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: North America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: United States: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: United States: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Canada: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Canada: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Asia-Pacific: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Asia-Pacific: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: China: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: China: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Japan: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Japan: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: India: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: India: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: South Korea: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: South Korea: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Australia: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Australia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Indonesia: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Indonesia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Europe: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Europe: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Germany: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Germany: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: France: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: France: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: United Kingdom: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: United Kingdom: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Italy: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Italy: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Spain: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 80: Spain: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Russia: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 82: Russia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 83: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 84: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 85: Latin America: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 86: Latin America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 87: Brazil: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 88: Brazil: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 89: Mexico: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 90: Mexico: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 91: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 92: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 93: Middle East and Africa: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 94: Middle East and Africa: Hemoglobinopathies Market: Breakup by Country (in %), 2021
Figure 95: Middle East and Africa: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 96: Global: Hemoglobinopathies Industry: SWOT Analysis
Figure 97: Global: Hemoglobinopathies Industry: Value Chain Analysis
Figure 98: Global: Hemoglobinopathies Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Hemoglobinopathies Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Hemoglobinopathies Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 3: Global: Hemoglobinopathies Market Forecast: Breakup by Treatment (in Million US$), 2022-2027
Table 4: Global: Hemoglobinopathies Market Forecast: Breakup by Test Type (in Million US$), 2022-2027
Table 5: Global: Hemoglobinopathies Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 6: Global: Hemoglobinopathies Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Hemoglobinopathies Market: Competitive Structure
Table 8: Global: Hemoglobinopathies Market: Key Players